Boehringer In­gel­heim deep­ens its col­lab­o­ra­tion with Click Ther­a­peu­tics in a deal worth $460M

Boehringer In­gel­heim inked a mas­sive col­lab­o­ra­tion with dig­i­tal ther­a­peu­tics com­pa­ny Click Ther­a­peu­tics two years ago — and now its ex­pand­ing.

On Mon­day, the Ger­man phar­ma an­nounced the launch of an “ex­pand­ed col­lab­o­ra­tion” be­tween Boehringer In­gel­heim and Click to de­vel­op and com­mer­cial­ize a sec­ond “pre­scrip­tion-based dig­i­tal ther­a­peu­tic.” The col­lab­o­ra­tion will cen­ter on schiz­o­phre­nia and aim to com­bine mul­ti­ple ther­a­peu­tic in­ter­ven­tions for use with phar­ma­ceu­ti­cal ther­a­py to help peo­ple with the dis­ease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER